Join TrialNet on the Pathway to Prevention.
Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of type 1 diabetes (T1D) years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.
- Relatives of people with T1D are 15 times more likely to develop the disease than the general population.
- Increased risk of developing T1D is linked to the presence of five diabetes-related autoantibodies, regardless if you have a relative or not.
- The JDRF, ADA and Endocrine Society now classify having two or more of these autoantibodies as early stage T1D.
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to prevent it. Offered through the TrialNet Pathway to Prevention Study, risk screening uses a simple blood test that can detect your risk of T1D years before symptoms appear. If you are in the early stages of T1D, you may be eligible for a prevention study. Take the first step and get screened.